HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab Completed Phase 2 Trials for Trastuzumab (DB00072)

IndicationStatusPhase
DBCOND0062717 (HER2-positive, Newly Diagnosed, Primary Breast Cancer, Neoadjuvant Therapy, Trastuzumab)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01816594NeoPHOEBE: Neoadjuvant Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive Primary Breast CancerTreatment